We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Levels of Genetic Material Predict Thyroid Cancer Recurrence

By LabMedica International staff writers
Posted on 18 Nov 2013
Print article
Image: miRCURY Locked Nucleic Acid (LNA) Universal RT microRNA polymerase chain reaction (PCR) kit (Photo courtesy of Exiqon).
Image: miRCURY Locked Nucleic Acid (LNA) Universal RT microRNA polymerase chain reaction (PCR) kit (Photo courtesy of Exiqon).
Elevated blood levels of the genetic material micro ribonucleic acid (miRNA) after surgery may indicate a higher possibility of recurrence post thyroidectomy. 

The presence of these short segments of this genetic material miRNA within papillary thyroid cancer tumors suggests a likelihood of recurrence after patients undergo surgery, which may be used to classify different types of thyroid tumors.

Scientists at the University of Sydney (NSW, Australia) recruited two groups retrospectively for the comparison of tissue miRNA expression in papillary thyroid cancer (PTC) with and without recurrence: patients with PTC who were diagnosed with recurrence after initial curative treatment and patients with PTC confined to the thyroid gland who had not been diagnosed with recurrence at their latest follow-up. Two additional groups were recruited prospectively for measurements of plasma miRNA levels: patients who had PTC without lateral lymph node or distant metastasis and were undergoing total thyroidectomy and patients who had multinodular goiter and were undergoing total thyroidectomy.

Total RNA was extracted from formalin-fixed, paraffin-embedded (FFPE) samples using the FFPE RNeasy Kit (Qiagen; Hilden, Germany). RNA samples were labeled with fluorescence Hy3 using the miRCURY Hy3/Hy5 power labeling kit and miRNA microarray profiling was performed on the miRCURY Locked Nucleic Acid (LNA) microRNA Array (Exiqon A/S; Vedbaek, Denmark). The expression levels of individual miRNAs were measured with quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) using TaqMan miRNA assays (Applied Biosystems; Foster City, CA, USA).

The investigators found that high levels of two specific miRNAs, miRNA-222 and miRNA-146b, within tumors indicated that cancer was more likely to recur after patients' tumors were surgically removed. The same two miRNAs were present at high levels in the blood of thyroid cancer patients compared with healthy individuals, but after thyroid surgery, the blood levels in the patients fell to normal levels.

The current blood test for the detection of recurrent papillary thyroid cancer is not accurate in up to a quarter of patients either because of interference from the patients' antibodies or other cancer-related factors. James Lee, MBBS, FRACS, the lead author of the study, said, “Our results suggest that we may be able to track the presence of papillary thyroid cancer by a microRNA blood test. An alternative blood test measuring microRNA levels would be a great complement to what is already available.” The study was published on October 28, 2013, in the journal Cancer. 

Related Links:

University of Sydney 
Qiagen 
Exiqon A/S


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
HPV Molecular Controls
ZeptoMetrix® HPV Type 16, 18, 45 & 68 Molecular Controls
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.